GSK Patient Assistance Program Will Cover Newly Approved Tykerb
Tyrosine kinase inhibitor clears FDA March 13 for use in combination with Roche’s Xeloda for second-line treatment of advanced or metastatic HER2 positive breast cancer.
Tyrosine kinase inhibitor clears FDA March 13 for use in combination with Roche’s Xeloda for second-line treatment of advanced or metastatic HER2 positive breast cancer.